SynthesisBMC cancer2023
Importance of endocrine treatment adherence and persistence in breast cancer survivorship: a systematic review.
Synthesis in BMC cancer, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
42 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Use of AI to Predict and Support Medication Adherence in Patients With Breast Cancer: Systematic Review.JMIR cancer · 2026Pooled it
- The impact of interprofessional collaboration between pharmacists and community health workers on medication adherence: a systematic review.International journal for equity in health · 2025Pooled it
- Double-dose firmonertinib as first-line treatment in patients with locally advanced or metastatic non-small-cell lung cancer harboring EGFR L858R mutation: a prospective, multicenter, phase II study (FIRM).Nature communications · 2026Trial
- Trial
- Pilot randomized controlled trial of a program to enhance experience and adherence with adjuvant endocrine therapy among women with non-metastatic breast cancer: 12-month quantitative results.Journal of cancer survivorship : research and practice · 2025Trial
- Associations Between HIV Infection Status, Psychosocial Factors, and Adjuvant Endocrine Therapy Adherence Among South African Women with Stage I-III Breast Cancer.International journal of behavioral medicine · 2026Article
- The FINE Index: A Frailty- and Immunonutrition-Based Nomogram for Survival in Geriatric Breast Cancer: A Retrospective Study.Cancer medicine · 2026Article
- Graded Exercise Therapy and Cognitive Behavioral Therapy for Fatigue in Patients With Breast Cancer: Protocol for a Randomized Controlled Pilot Study.JMIR research protocols · 2026Article
- Enhancing medication adherence with blister-packed oral oncolytics: A case example in chronic lymphocytic leukemia.Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners · 2026Article
- Tamoxifen Reduces Breast Cancer Recurrence in Women with DCIS Who Underwent Mastectomy.Current oncology (Toronto, Ont.) · 2026Article
- Identification of factors associated with non-adherence to oral endocrine therapy in breast cancer patients of low socioeconomic status: a single centre retrospective study.International journal of clinical pharmacy · 2026Article
- Adherence to endocrine therapy and survival outcomes in hormone receptor-positive breast cancer.Frontiers in oncology · 2026Article
- A Systematic Review of Methods to Measure Adherence to Oral Anticancer Medications in African Women With Breast Cancer at Initiation, Implementation, and Discontinuation of Therapy.International journal of breast cancer · 2026Review
- Patient-reported outcome measures (PROMs) capturing therapy adherence of cancer patients: an umbrella review.Patient related outcome measures · 2026Review
- Adherence to adjuvant endocrine therapy in breast cancer: a single regional Australian centre experience.Frontiers in oncology · 2026Article
- Impact of Side Effects on 5-Year Adherence to Adjuvant Endocrine Therapy in Women with Breast Cancer: An Integrative Review.International journal of women's health · 2026Review
- Primary Well-Differentiated Neuroendocrine Tumor of the Breast: A Case Report and Literature Review.The American journal of case reports · 2025Review
- Prescription and self-reported use of endocrine therapy among Black hormone receptor-positive breast cancer survivors in the Detroit Research on Cancer Survivors cohort.Breast cancer research and treatment · 2025Article
- Adherence to oral anticancer medications in metastatic versus nonmetastatic breast cancer patients: Insights from a low-middle-income country.Exploratory research in clinical and social pharmacy · 2025Article
- Multimodal Sensing and Modeling of Endocrine Therapy Adherence in Breast Cancer Survivors.Proceedings of the ACM on interactive, mobile, wearable and ubiquitous technologies · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeAdjuvant endocrine treatment is essential for treating luminal subtypes of breast cancer, which constitute 75% of all breast malignancies. However, the detrimental side effects of treatment make it difficult for many patients to complete the guideline-required treatment. Such non-adherence may jeopardize the lifesaving ability of anti-estrogen therapy. In this systematic review, we aimed to assess the consequences of non-adherence and non-persistence from available studies meeting strict statistical and clinical criteria.
methodsA systematic literature search was performed using several databases, yielding identification of 2,026 studies. After strict selection, 14 studies were eligible for systematic review. The review included studies that examined endocrine treatment non-adherence (patients not taking treatment as prescribed) or non-persistence (patients stopping treatment prematurely), in terms of the effects on event-free survival or overall survival among women with non-metastatic breast cancer.
resultsWe identified 10 studies measuring the effects of endocrine treatment non-adherence and non-persistence on event-free survival. Of these studies, seven showed significantly poorer survival for the non-adherent or non-persistent patient groups, with hazard ratios (HRs) ranging from 1.39 (95% CI, 1.07 to 1.53) to 2.44 (95% CI, 1.89 to 3.14). We identified nine studies measuring the effects of endocrine treatment non-adherence and non-persistence on overall survival. Of these studies, seven demonstrated significantly reduced overall survival in the groups with non-adherence and non-persistence, with HRs ranging from 1.26 (95% CI, 1.11 to 1.43) to 2.18 (95% CI, 1.99 to 2.39).
conclusionThe present systematic review demonstrates that non-adherence and non-persistence to endocrine treatment negatively affect event-free and overall survival. Improved follow-up, with focus on adherence and persistence, is vital for improving health outcomes among patients with non-metastatic breast cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.